Publication Name	World Journal of Hepatology
Manuscript ID	68985
Country	United Kingdom

Received	2021-06-11 09:04
Peer-Review Started	2021-06-11 09:09
To Make the First Decision
Return for Revision	2021-07-06 01:49
Revised	2021-07-19 07:57
Second Decision	2021-09-14 03:39
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2021-09-17 02:01
Articles in Press	2021-09-17 02:01
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-11-19 00:35
Publish the Manuscript Online	2021-11-24 09:54

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pediatrics
Manuscript Type	Minireviews
Article Title	Cystic fibrosis associated liver disease in children
Manuscript Source	Invited Manuscript
All Author List	Joseph J Valamparampil and Girish L Gupte
ORCID	Author(s) ORCID Number Joseph J Valamparampil http://orcid.org/0000-0002-8114-2523 Girish L Gupte http://orcid.org/0000-0002-9026-1583
Funding Agency and Grant Number
Corresponding Author	Girish L Gupte, MD, Consultant Physician-Scientist, Liver Unit, Birmingham Children’s Hospital, Steelhouse Lane, Birmingham B4 6NH, United Kingdom. girishgupte@nhs.net
Key Words	Cystic fibrosis liver disease; Portal hypertension; Cirrhosis; Liver transplantation; Cystic fibrosis transmembrane conductance regulator modulators; Distal intestinal obstructive syndrome
Core Tip	Cystic fibrosis liver disease is caused by abnormal cholangiocyte function, altered biliary secretion and abnormal innate immune response with abnormal response to endotoxins. Cystic fibrosis liver disease can present with a wide variety of clinical features from a heterogenous liver on ultrasound, to life threatening gastrointestinal bleeds secondary to portal hypertension. Novel treatment strategies directly targeting the ion channel abnormality-cystic fibrosis transmembrane conductance regulator modulators are available and has significantly improved the clinical status and life expectancy of the cystic fibrosis patients.
Publish Date	2021-11-24 09:54
Citation	Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease in children. World J Hepatol 2021; 13(11): 1727-1742
URL	https://www.wjgnet.com/1948-5182/full/v13/i11/1727.htm
DOI	https://dx.doi.org/10.4254/wjh.v13.i11.1727

Full Article (PDF)	WJH-13-1727.pdf
Full Article (Word)	WJH-13-1727.docx
Manuscript File	68985_Auto_Edited.docx
Answering Reviewers	68985-Answering reviewers.pdf
Audio Core Tip	68985-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	68985-Conflict-of-interest statement.pdf
Copyright License Agreement	68985-Copyright license agreement.pdf
Peer-review Report	68985-Peer-review(s).pdf
Scientific Editor Work List	68985-Scientific editor work list.pdf
CrossCheck Report	68985-CrossCheck report.pdf